Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 9, 2008, Pages 1672-1678

  Lamon Fava, Stefania ^a   Diffenderfer, Margaret R ^a   Barrett, P Hugh R ^b   Buchsbaum, Aaron ^a   Nyaku, Mawuli ^a   Horvath, Katalin V ^a   Asztalos, Bela F ^a   Otokozawa, Seiko ^a   Ai, Masumi ^a   Matthan, Nirupa R ^a   Lichtenstein, Alice H ^a   Dolnikowski, Gregory G ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoprotein; High density lipoprotein; Kinetics; Lipid lowering medications; Triglyceride

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOVASTATIN PLUS NICOTINIC ACID; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; APOA1 PROTEIN, HUMAN; APOA2 PROTEIN, HUMAN; APOLIPOPROTEIN A2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ADULT; AGED; ARTICLE; CASE REPORT; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HYPERLIPIDEMIA; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DELAYED RELEASE FORMULATION; DRUG COMBINATION; LIPID METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KINETICS; LIPID METABOLISM; LOVASTATIN; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 51649127816     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.164541     Document Type: Article

References (39)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid, on serum cholesterol in man. Arch Biochem. 1955;54:558-559.
2. The Coronary Drug Project Research Group. Clofibrate and. niacin in coronary heart disease. JAMA. 1975;231:360-381.
3. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald WT. Fifteen year mortality in Coronary Drug Project patients: long-term, benefits with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
4. Brown. G, Albers JJ, Fisher L, Schaefer SM, Lin. JT, Kaplan C, Zha o XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with, high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Brown. B, Zhao X, Chait A, Fisher L, Cheung M, Morse J, Dowdy A, Marino E, Bolsón. E, Alaupovic P, Fröhlich J, Albers J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 2001;345:1583-1592.
6. Taylor AJ, Sullenberger LE, Lee HJ, Lee J, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
7. Capuzzi DM, Guyton JR, Morgan. J, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an. extended-release niacin. (Niaspan): a long-term, study. Am J Cardiol. 1998;82:74U-81U.
8. Carlson. LA, Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand. 1962;172:641-645.
9. Kushwaha RS, Haffner S, Foster DM, Hazzard WR. Compositional and metabolic heterogeneity of apha2 and beta-very-low-density lipoproteins in subjects with broad beta disease and endogenous hypertriglyceridemia. Metabolism. 1985;34:1029-1038.
10. Blum. CB, Levy RI, Eisenberg S, Hall M III, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977;60: 795-807.
11. Shepherd J, Packard CJ, Patsch. JR, Gotto AM, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63:858-867.
12. The Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program. (NCEP) Expert Panel on Detection, Evaluation, and. Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. Cohn J, Wagner D, Cohn S, Millar J, Schaefer EJ. Measurement of very low density and low density lipoprotein, apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effects of fasting and feeding. J Clin Invest. 1990;85: 804-811.
14. Lamon-Fava S, Diffenderfer M, Barrett PH, Buchsbaum. A, Matthan. N, Lichtenstein AH, Dolnikowski GG, Horvath KV, Asztalos BF, Zago V, Schaefer EI. Effects of different doses of atorvastatin on human, apolipoprotein B-100, B-48, and. A-I metabolism. J Lipid Res. 2007;48: 1746-1753.
15. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma lipoprotein, fractions. Clin Chim Acta. 1987; 166:1-8.
16. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291-300.
17. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007;53:2128-2135.
18. Havel RJ, Eder H, Bragdon J. The distribution, and chemical composition of ultracentrifugally separated lipoprotein in. human serum. J Clin Invest. 1955;34:1345-1363.
19. Dwyer KP, Barrett PH, Chan D, Foo JI, Watts GF, Croft KD. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method, for stable isotope kinetic studies of lipoproteins. J Lipid Res. 2002:43: 344-349.
20. Cobelli C, Toffolo G, Bier D, Nosadini R. Models to interpret kinetic data in. stable isotope tracer studies. Am J Physiol. 1987;253:E551-E564.
21. Lamon-Fava S, Postfai B, Diffenderfer M, deLuca C, O'Connor J Jr, Welty FK, Dolnikowski GG, Barrett P, Schaefer EJ. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. Arterioscler Thromb Vase Biol. 2006; 26:385-391.
22. Parhofer K, Barrett P, Bier D, Schonfeld G. Determination of kinetic parameters od apolipoprotein. B metabolism using amino acids labeled, with stable isotopes. J Lipid Res. 1991;8:1311-1323.
23. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. 2002;324:61-71.
24. Kamei T, Tuji N, Taketani K, Nakamoto M, Yamaguchi F, Sasaki A, Nabiki J, Ikeda M, Tabata N, Kudo T, Harano Y. Evaluation and clinical significance of latex immunoassay (LIA) of insulin using the routine biochemical autoanalyzer. Clin Chem. (Japan). 2006;35:48-53.
25. Nishimura A, Sawai T. Determination, of adiponectin. in. serum using a latex particle-enhanced turbidimetric immunoassay with an autoanalyzer. Clin Chim Acta. 2006;371:163-168.
26. Matthan N, Giovanni A, Schaefer EJ, Brown B, Lichtenstein AH. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res. 2003;44:800-806.
27. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas R. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743-745.
28. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of highdensity lipoprotein, apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Arterioscler Thromb Vase Biol. 1997;17:2020-2028.
29. Marsh. J, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr Opin Lipidol, 2000;11:261-266.
30. Osborne JC, Schaefer EJ, Powell GM, Lee NS, Zech LA. Molecular properties of radioiodinated apolipoprotein. A-I. J Biol Chem, 1984;259: 347-353.
31. Watt MJ, Southgate RJ, Holmes AG, Febbraio MA. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator lalpha in human, skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol. 2004; 33:533-544.
32. Lamon-Fava S, Micherone D. Regulation of apo A-I gene expression: mechanism of action of estrogen and. genistein. J Lipid Res. 2004;45: 106-112.
33. Pandey NR, Renwick J, Misquith A, Sokoli K, Sparks DL. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein secretion. Biochemistry. 2008;47:1579-1587.
34. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallai G, Morse JS, Brown GB, Schaefer EJ. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vase Biol, 2003;23:847-582.
35. Chan D, Watts GF, Nguyen. MN, Barrett P. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nu.tr. 2006;84:37-43.
36. Carlson LA, Ostman. J. Inhibition, of the mobilization of free fatty acids form adipose tissue in diabetes. II. Effect of nicotinic acid, and acetylsalicylate on blood glucose in human, diabetics. Acta Med Scand. 1965; 178: 71-79.
37. Vega GL, Cater NB, Meguro S, Grundy SM. Influence of extendedrelease nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol. 2005;95: 1309-1313.
38. Wang W, Basinger A, Neese RA, Shane B, Myong S-A, Christiansen. M, Hellerstein MK. Effect of nicotinic acid, administration on hepatic very low-desnity lipoprotein-triglyceride production. Am. J Physiol Endocrinol Metab. 2001;43:E540-E547.
39. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGATl activity in HepG2 cells. J Lipid Res. 2004;45:1835-1845.